Related references
Note: Only part of the references are listed.Global prediction of primary liver cancer incidences and mortality in 2040
Chenxi Li et al.
JOURNAL OF HEPATOLOGY (2023)
A normalized drug response metric improves accuracy and consistency of anticancer drug sensitivity quantification in cell-based screening
Abhishekh Gupta et al.
COMMUNICATIONS BIOLOGY (2020)
Applicability of drug response metrics for cancer studies using biomaterials
Elizabeth A. Brooks et al.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2019)
A Multi-center Study on the Reproducibility of Drug-Response Assays in Mammalian Cell Lines
Mario Niepel et al.
CELL SYSTEMS (2019)
A visual tool for defining reproducibility and replicability
Prasad Patil et al.
NATURE HUMAN BEHAVIOUR (2019)
Drug repurposing: progress, challenges and recommendations
Sudeep Pushpakom et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
PharmacoDB: an integrative database for mining in vitro anticancer drug screening studies
Petr Smirnov et al.
NUCLEIC ACIDS RESEARCH (2018)
Human serum alters cell culture behavior and improves spheroid formation in comparison to fetal bovine serum
Julia I. Heger et al.
EXPERIMENTAL CELL RESEARCH (2018)
Optimized alamarBlue assay protocol for drug dose-response determination of 3D tumor spheroids
Christoph Eilenberger et al.
METHODSX (2018)
Alternative drug sensitivity metrics improve preclinical cancer pharmacogenomics
Marc Hafner et al.
NATURE BIOTECHNOLOGY (2017)
Long-term growth comparison studies of FBS and FBS alternatives in six head and neck cell lines
Chih-Yeu Fang et al.
PLOS ONE (2017)
Analysis of variability in high throughput screening data: applications to melanoma cell lines and drug responses
Kuan-Fu Ding et al.
ONCOTARGET (2017)
Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics
Marc Hafner et al.
SCIENTIFIC DATA (2017)
GRcalculator: an online tool for calculating and mining dose-response data
Nicholas A. Clark et al.
BMC CANCER (2017)
Reproducible pharmacogenomic profiling of cancer cell line panels
Peter M. Haverty et al.
NATURE (2016)
Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs
Marc Hafner et al.
NATURE METHODS (2016)
Screening out irrelevant cell-based models of disease
Peter Horvath et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
mQC: A Heuristic Quality-Control Metric for High-Throughput Drug Combination Screening
Lu Chen et al.
SCIENTIFIC REPORTS (2016)
Different Cell Viability Assays Reveal Inconsistent Results After Bleomycin Electrotransfer In Vitro
Baltramiejus Jakstys et al.
JOURNAL OF MEMBRANE BIOLOGY (2015)
Pharmacogenomic agreement between two cancer cell line data sets
Nicolas Stransky et al.
NATURE (2015)
A first approach to evaluate the cell dose in highly porous scaffolds by using a nondestructive metabolic method
Carla Divieto et al.
FUTURE SCIENCE OA (2015)
Enhancing Reproducibility in Cancer Drug Screening: How Do We Move Forward?
Christos Hatzis et al.
CANCER RESEARCH (2014)
Cisplatin in cancer therapy: Molecular mechanisms of action
Shaloam Dasari et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Clinical development success rates for investigational drugs
Michael Hay et al.
NATURE BIOTECHNOLOGY (2014)
Multiplexing Spheroid Volume, Resazurin and Acid Phosphatase Viability Assays for High-Throughput Screening of Tumour Spheroids and Stem Cell Neurospheres
Delyan P. Ivanov et al.
PLOS ONE (2014)
Oncology Drug Discovery: Planning a Turnaround
Carlo Toniatti et al.
CANCER DISCOVERY (2014)
Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies
Bhagwan Yadav et al.
SCIENTIFIC REPORTS (2014)
A Genome-wide siRNA Screen Identifies Proteasome Addiction as a Vulnerability of Basal-like Triple-Negative Breast Cancer Cells
Fabio Petrocca et al.
CANCER CELL (2013)
Inconsistency in large pharmacogenomic studies
Benjamin Haibe-Kains et al.
NATURE (2013)
High-Throughput 3D Screening Reveals Differences in Drug Sensitivities between Culture Models of JIMT1 Breast Cancer Cells
Vesa Hongisto et al.
PLOS ONE (2013)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
Quality control of cell-based high-throughput drug screening
Zhiyun Zhang et al.
ACTA PHARMACEUTICA SINICA B (2012)
Automatic Liquid Handling for Life Science: A Critical Review of the Current State of the Art
Fanwei Kong et al.
JALA (2012)
High drug attrition rates-where are we going wrong?
Lisa Hutchinson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Believe it or not: how much can we rely on published data on potential drug targets?
Florian Prinz et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
A comparison of assay performance measures in screening assays:: Signal window, Z′ factor, and assay variability ratio
PW Iversen et al.
JOURNAL OF BIOMOLECULAR SCREENING (2006)
Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity
J O'Brien et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2000)
Share Paper
